New cancer drug enters human testing for advanced tumors
NCT ID NCT05991349
Summary
This early-stage study tested a new cancer drug called IBI129 in people with advanced solid tumors that cannot be removed by surgery. The main goals were to find a safe and effective dose and to see how the body processes the drug. About 180 adults with various types of advanced cancer participated to help researchers understand if this treatment is promising for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chris O'Brien Lifehouse
Camperdown, New South Wales, 2050, Australia
-
Hubei Cancer Hospital
Wuhan, Hubei, China
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
St George private Hospital
Kogarah, New South Wales, 2217, Australia
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
Tianjin Medical university cancer institute & Hospital
Tianjin, Tianjin Municipality, 300000, China
-
Wollongong Hospital
Wollongong, New South Wales, 2500, Australia
Conditions
Explore the condition pages connected to this study.